Company intelligence / Profile preview

Topaz Pharmaceuticals, Inc.

Jenkintown / Horsham / Doylestown*, Pennsylvania, United Stateszoominfo.com ↗

Ownership: Private
Development stage: NDA

Overview

Lead asset was a topical 0.5% ivermectin cream for the treatment of head lice. The company completed Phase 3 trials demonstrating safety and efficacy prior to its acquisition. No ongoing clinical programs as an independent company.[2]

Therapeutic areas: OtherInfectious Diseases
Modalities: Small molecules (notably topical ivermectin cream for head lice)
Industry: Biotech

Drug pipeline

1 asset

ivermectin

NDA

Indications: Head lice

Beyond the preview

Go deeper on Topaz Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Topaz Pharmaceuticals, Inc..

Explore the full profile